Valeant Pharmaceuticals, the most widely held name in U.S. CLOs, announced last week it was cutting its revenue forecast and that a delay in filing its annual report put the company at risk of defaulting on its debt. In response, Valeant’s shares plunged by more than 50%. The company’s loans ended Tuesday with a weighted average bid of 94. While it is the most widely held name in U.S. CLOs, with holdings totaling US$3.8bn, it still represents only 0.9% of CLO assets, based on the most recent data available in LPC Collateral. 
Valeant is held by 754 U.S. CLOs, with 53% of deals having sub-1% exposure. On the other hand, 7% of CLOs have exposure in the 2-3% range, with 1% of deals having exposure above 3% of assets. In terms of trading activity, since the middle of last year CLOs have bought US$625m of Valeant (at a weighted average price of 96.93) and sold US$541m (at an average price of 93.77). After Valeant, the most widely held names in U.S. CLOs are First Data Corp. (US$3.4bn), Asurion Corp. (US$3.1bn), and Albertson (US$2.8bn.).
Register now! TR LPC’s 4th Annual Middle Market Loans Conference on April 27, 2016.
Contact: Colm Doherty
colm.doherty@thomsonreuters.com
Latest news
US Leveraged Loans Return 3.36% to Investors YTD
The Bloomberg US Leveraged Loan Index (Ticker: LOAN) returned 0.96% in August and has gained an additional 0.28% through September…
PE dry powder
The capital that is being raised is flowing overwhelmingly to the largest, most established managers.
Middle market debt held by BDCs vs High yield vs Treasury yields
The blue line represents the current dividend yield of the VanEck BDC Income ETF (BIZD), which stood at 11.7% as…